{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:29:05Z","timestamp":1790281745206,"version":"4.1.0"},"reference-count":35,"publisher":"Mattioli1885","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Psoriasis and bullous pemphigoid\u00a0(BP)\u00a0are the 2 major types of immune-mediated inflammatory\u00a0skin diseases. Studies have reported the\u00a0association between psoriasis and BP; however, no studies reported whether a causal relationship exists between these 2 skin diseases. Objectives: In order to explore the causal relationship between psoriasis and BP, we performed a bidirectional two-sample Mendelian randomization (MR) study. Methods: Genome-wide association study (GWAS) data related to psoriasis\u00a0and BP were collected. The inverse variance weighted (IVW) method was primarily applied for our MR analysis, MR-Egger, weighted median, simple mode, and weighted mode methods were\u00a0used additionally. Heterogeneity, horizontal pleiotropy, and potential outliers were assessed for the MR analysis results. Results: GWAS data for psoriasis (3 cohorts) and BP (1 cohort) from publicly available trials were selected. Our MR results showed that psoriasis\u00a0was\u00a0causally associated with BP, psoriasis could increase the risk of BP, reversed MR showed BP has no causal effect on psoriasis. No heterogeneity or pleiotropy was detected.\u00a0 Conclusion: These findings provided new evidence of the causal relationship between psoriasis and BP,\u00a0our MR\u00a0suggested\u00a0that psoriasis is potentially causal to BP, which help us improving the treatment strategy for patients with psoriasis. The mechanism remains open for further investigation.<\/jats:p>","DOI":"10.5826\/dpc.1501a4458","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:19:58Z","timestamp":1738153198000},"page":"4458","source":"Crossref","is-referenced-by-count":2,"title":["Causal Relationship Between Psoriasis and Bullous Pemphigoid: A Mendelian Randomization Analysis"],"prefix":"10.5826","volume":"15","author":[{"given":"Xiaoxue","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zexin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The Comprehensive Breast Care Center, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"10.5826\/dpc.1501a4458_ref1","doi-asserted-by":"crossref","unstructured":"Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Signaling pathways and targeted therapies for psoriasis. Signal Transduct Target Ther. 2023;8(1):1-38. DOI: 10.1038\/s41392-023-01655-6. PMID: 38008779.","DOI":"10.1038\/s41392-023-01655-6"},{"key":"10.5826\/dpc.1501a4458_ref2","doi-asserted-by":"crossref","unstructured":"Iversen L, Daud\u00e9n E, Segaert S, et al. Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. J Eur Acad Dermatol Venereol. 2017;31(8):1271-1284. DOI: 10.1111\/jdv.14277. PMID: 28419600.","DOI":"10.1111\/jdv.14277"},{"key":"10.5826\/dpc.1501a4458_ref3","doi-asserted-by":"crossref","unstructured":"Krajina I, Stupin A, \u0160ola M, Mihalj M. Oxidative stress induced by high salt diet\u2014possible implications for development and clinical manifestation of cutaneous inflammation and endothelial dysfunction in psoriasis vulgaris. Antioxidants (Basel). 2022;11(7):1269. DOI: 10.3390\/antiox11071269. PMID: 35883760.","DOI":"10.3390\/antiox11071269"},{"key":"10.5826\/dpc.1501a4458_ref4","doi-asserted-by":"crossref","unstructured":"Meyer N, Paul C, Feneron D, et al. Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol. 2010;24(9):1075-1082. DOI: 10.1111\/j.1468-3083.2010.03600.x. PMID: 20236205.","DOI":"10.1111\/j.1468-3083.2010.03600.x"},{"key":"10.5826\/dpc.1501a4458_ref5","doi-asserted-by":"crossref","unstructured":"Sahi FM, Masood A, Danawar NA, Mekaiel A, Malik BH. Association between psoriasis and depression: a traditional review. Cureus. 2020;12(8):e9708. DOI: 10.7759\/cureus.9708. PMID: 32944430.","DOI":"10.7759\/cureus.9708"},{"key":"10.5826\/dpc.1501a4458_ref6","doi-asserted-by":"crossref","unstructured":"Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13(10):1461-1473. DOI: 10.1080\/17425247.2016.1188801. PMID: 27164301.","DOI":"10.1080\/17425247.2016.1188801"},{"key":"10.5826\/dpc.1501a4458_ref7","doi-asserted-by":"crossref","unstructured":"Hammers CM, Stanley JR. Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol. 2016;11(1):175-197. DOI: 10.1146\/annurev-pathol-012615-044313. PMID: 26907530.","DOI":"10.1146\/annurev-pathol-012615-044313"},{"key":"10.5826\/dpc.1501a4458_ref8","doi-asserted-by":"crossref","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population-based cohort study. BMJ. 2008;337:a180. DOI: 10.1136\/bmj.a180. PMID: 18614511.","DOI":"10.1136\/bmj.a180"},{"key":"10.5826\/dpc.1501a4458_ref9","doi-asserted-by":"crossref","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320-332. DOI: 10.1016\/S0140-6736(12)61140-4. PMID: 23237497.","DOI":"10.1016\/S0140-6736(12)61140-4"},{"key":"10.5826\/dpc.1501a4458_ref10","doi-asserted-by":"crossref","unstructured":"Kirtschig G, Middleton P, Bennett C, Murrell DF, Wojnarowska F, Khumalo NP. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292. DOI: 10.1002\/14651858.CD002292.pub3. PMID: 20927731.","DOI":"10.1002\/14651858.CD002292.pub3"},{"key":"10.5826\/dpc.1501a4458_ref11","doi-asserted-by":"crossref","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case\u2013control study. J Invest Dermatol. 2011;131(3):637-643. DOI: 10.1038\/jid.2010.301. PMID: 20944650.","DOI":"10.1038\/jid.2010.301"},{"key":"10.5826\/dpc.1501a4458_ref12","doi-asserted-by":"crossref","unstructured":"Ho YH, Hu HY, Chang YT, Li CP, Wu CY. Psoriasis is associated with increased risk of bullous pemphigoid: a nationwide population-based cohort study in Taiwan. J Dermatol. 2019;46(7):604-609. DOI: 10.1111\/1346-8138.14902. PMID: 31062428.","DOI":"10.1111\/1346-8138.14902"},{"key":"10.5826\/dpc.1501a4458_ref13","doi-asserted-by":"crossref","unstructured":"Mounier N, Kutalik Z. Bias correction for inverse variance weighting Mendelian randomization. Genet Epidemiol. 2023;47(4):314-331. DOI: 10.1002\/gepi.22522. PMID: 37036286.","DOI":"10.1002\/gepi.22522"},{"key":"10.5826\/dpc.1501a4458_ref14","doi-asserted-by":"crossref","unstructured":"Wang K. Interval estimate of causal effect in summary data-based Mendelian randomization in the presence of winner\u2019s curse. Genet Epidemiol. 2024;48(2):74-84. DOI: 10.1002\/gepi.22545. PMID: 38282283.","DOI":"10.1002\/gepi.22545"},{"key":"10.5826\/dpc.1501a4458_ref15","doi-asserted-by":"crossref","unstructured":"Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36(11):1783-1802. DOI: 10.1002\/sim.7221. PMID: 28114746.","DOI":"10.1002\/sim.7221"},{"key":"10.5826\/dpc.1501a4458_ref16","doi-asserted-by":"crossref","unstructured":"Boef AGC, Dekkers OM, le Cessie S. Mendelian randomization studies: a review of the approaches used and the quality of reporting. Int J Epidemiol. 2015;44(2):496-511. DOI: 10.1093\/ije\/dyv071. PMID: 25953784.","DOI":"10.1093\/ije\/dyv071"},{"key":"10.5826\/dpc.1501a4458_ref17","doi-asserted-by":"crossref","unstructured":"Sakaue S, Kanai M, Tanigawa Y, et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat Genet. 2021;53(10):1415-1424. DOI: 10.1038\/s41588-021-00931-x. PMID: 34594039.","DOI":"10.1038\/s41588-021-00931-x"},{"key":"10.5826\/dpc.1501a4458_ref18","doi-asserted-by":"crossref","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-525. DOI: 10.1093\/ije\/dyv080. PMID: 26050253.","DOI":"10.1093\/ije\/dyv080"},{"key":"10.5826\/dpc.1501a4458_ref19","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945. DOI: 10.1001\/jama.2020.4006. PMID: 32427307.","DOI":"10.1001\/jama.2020.4006"},{"key":"10.5826\/dpc.1501a4458_ref20","doi-asserted-by":"crossref","unstructured":"Conrad C, Gilliet M. Psoriasis: from pathogenesis to targeted therapies. Clin Rev Allergy Immunol. 2018;54(1):102-113. DOI: 10.1007\/s12016-018-8668-1. PMID: 29349534.","DOI":"10.1007\/s12016-018-8668-1"},{"key":"10.5826\/dpc.1501a4458_ref21","doi-asserted-by":"crossref","unstructured":"Teng MWL, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719-729. DOI: 10.1038\/nm.3895. PMID: 26121196.","DOI":"10.1038\/nm.3895"},{"key":"10.5826\/dpc.1501a4458_ref22","doi-asserted-by":"crossref","unstructured":"Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17-26. DOI: 10.1038\/jid.2012.194. PMID: 22673731.","DOI":"10.1038\/jid.2012.194"},{"key":"10.5826\/dpc.1501a4458_ref23","doi-asserted-by":"crossref","unstructured":"Hu P, Wang M, Gao H, et al. The role of helper T cells in psoriasis. Front Immunol. 2021;12:788940. DOI: 10.3389\/fimmu.2021.788940. PMID: 34975883.","DOI":"10.3389\/fimmu.2021.788940"},{"key":"10.5826\/dpc.1501a4458_ref24","doi-asserted-by":"crossref","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022;13(1):81. DOI: 10.1038\/s41419-022-04523-3. PMID: 35075118.","DOI":"10.1038\/s41419-022-04523-3"},{"key":"10.5826\/dpc.1501a4458_ref25","doi-asserted-by":"crossref","unstructured":"Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase\u2013signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. DOI: 10.1016\/j.jaad.2021.06.869. PMID: 34224773.","DOI":"10.1016\/j.jaad.2021.06.869"},{"key":"10.5826\/dpc.1501a4458_ref26","doi-asserted-by":"crossref","unstructured":"Liang J, Chen P, Li C, et al. IL-22 down-regulates Cx43 expression and decreases gap junctional intercellular communication by activating the JNK pathway in psoriasis. J Invest Dermatol. 2019;139(2):400-411. DOI: 10.1016\/j.jid.2018.07.032. PMID: 30171832.","DOI":"10.1016\/j.jid.2018.07.032"},{"key":"10.5826\/dpc.1501a4458_ref27","doi-asserted-by":"crossref","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2019;182(4):840-848. DOI: 10.1111\/bjd.18245. PMID: 31225638.","DOI":"10.1111\/bjd.18245"},{"key":"10.5826\/dpc.1501a4458_ref28","doi-asserted-by":"crossref","unstructured":"Vik\u00e1r S, Szilveszter KP, Koszor\u00fa K, S\u00e1rdy M, M\u00f3csai A. The Syk inhibitor entospletinib abolishes dermal-epidermal separation in a fully human ex vivo model of bullous pemphigoid. J Invest Dermatol. 2024;144(8):1733-1742. DOI: 10.1016\/j.jid.2024.01.009. PMID: 38296021.","DOI":"10.1016\/j.jid.2024.01.009"},{"key":"10.5826\/dpc.1501a4458_ref29","doi-asserted-by":"crossref","unstructured":"D\u00edaz LA, Ratrie H, Saunders WS, et al. Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome. J Clin Invest. 1990;86(4):1088-1094. DOI: 10.1172\/jci114812. PMID: 1698819.","DOI":"10.1172\/JCI114812"},{"key":"10.5826\/dpc.1501a4458_ref30","doi-asserted-by":"crossref","unstructured":"Stanley JR, Hawley-Nelson P, Yuspa SH, Shevach EM, Katz SI. Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified squamous epithelia. Cell. 1981;24(3):897-903. DOI: 10.1016\/0092-8674(81)90115-x. PMID: 7018697.","DOI":"10.1016\/0092-8674(81)90115-X"},{"key":"10.5826\/dpc.1501a4458_ref31","doi-asserted-by":"crossref","unstructured":"Schmidt EE, Reimer S, Jainta S, et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol. 2000;115(5):842-848. DOI: 10.1046\/j.1523-1747.2000.00141.x. PMID: 11069622.","DOI":"10.1046\/j.1523-1747.2000.00141.x"},{"key":"10.5826\/dpc.1501a4458_ref32","doi-asserted-by":"crossref","unstructured":"Kridin K, Bergman R. Association between bullous pemphigoid and psoriasis: A case-control study. J Am Acad Dermatol. 2017;77(2):370-372. DOI: 10.1016\/j.jaad.2017.02.057. PMID: 28711088.","DOI":"10.1016\/j.jaad.2017.02.057"},{"key":"10.5826\/dpc.1501a4458_ref33","doi-asserted-by":"crossref","unstructured":"Phan K, Goyal S, Murrell DF. Association between bullous pemphigoid and psoriasis: systematic review and meta-analysis of case-control studies. Australas J Dermatol. 2018;60(1):23-28. DOI: 10.1111\/ajd.12899. PMID: 30141189.","DOI":"10.1111\/ajd.12899"},{"key":"10.5826\/dpc.1501a4458_ref34","doi-asserted-by":"crossref","unstructured":"Su F, Wang T, Qin Q, Xie Z. Upadacitinib for the management of bullous pemphigoid coexisting with psoriasis vulgaris: a case report and literature review. J Dermatol Treat. 2024;35(1):e2302394. DOI: 10.1080\/09546634.2024.2302394. PMID: 38263708.","DOI":"10.1080\/09546634.2024.2302394"},{"key":"10.5826\/dpc.1501a4458_ref35","doi-asserted-by":"crossref","unstructured":"Ho PH, Tsai TF. Development of bullous pemphigoid during secukinumab treatment for psoriasis. J Dermatol. 2017;44(9):e220-e221. DOI: 10.1111\/1346-8138.13909. PMID: 28543960.","DOI":"10.1111\/1346-8138.13909"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4458\/2997","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4458\/3424","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4458\/2996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T15:23:31Z","timestamp":1762442611000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/4458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1501a4458","relation":{"has-manifestation":[{"id-type":"other","id":"1-78-4458-g2996","asserted-by":"subject"},{"id-type":"other","id":"1-78-4458-g2997","asserted-by":"subject"},{"id-type":"other","id":"1-78-4458-g3424","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.v15i1","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"5"}}